Key facts
- It has raised $3.5M; the latest was Seed Round ($3.5M) in Mar 2026.
- Notable investors include Seedcamp, Defined, Merantix Capital, Openseed VC.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Outpost Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Outpost Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Outpost Bio
Developer of microbiome-focused tools and wet lab methods intended to make human microbial ecosystems computable for drug efficacy, personalized medicine, and nutrient absorption. The company pairs novel wet lab human microbiology with machine learning and high-performance computing to decode hidden microbe-host interactions and reveal the final frontier of human biology, enabling biopharmaceutical and healthcare stakeholders to unlock a new era of more personalized, predictive medicine and improved therapeutic discovery efficiency.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2025
- Employees
- 9
- Website
- outpost.bio/
- Ownership
- Privately Held (backing)
Outpost Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Outpost Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Outpost Bio in its N-PORT filings yet. We sweep new filings monthly.